Keywords: Small-molecule cancer drugs, Market forecasts, Visiongain

Small-molecule cancer drug revenues set to reach $27.3 billion in 2015, predicts Visiongain

Article | 07 November 2011

Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate the small-molecule targeted cancer drug market, leading the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in